



Republic of the Philippines  
Department of Health  
**OFFICE OF THE SECRETARY**

11 January 2018

**CERTIFICATION**


This is to certify the one (1) year provisional exemption from Executive Order No. 49 s. 1993 (*Directing the Mandatory Use of the Philippine National Drug Formulary (PNDF) Volume I as the Basis for Procurement of Drug Products by the Government*), effective upon receipt of this certificate, of the following medicine:

Medicine: **Daclatasvir 90 mg tablet**

Indication: For the treatment of hepatitis C genotypes 1, 2, 3, and 4 in combination with sofosbuvir +/- ribavirin.

The product shall only be utilized by the requesting party – the Disease Prevention and Control Bureau (DPCB). Likewise, the concerned proponent shall provide the Formulary Executive Council (FEC), through the Pharmaceutical Division, the following documents at the end of exemption validity: (1) local efficacy and safety profile; (2) surveillance report on adverse effects; (3) registry of patients; and (4) impact study/outcomes of patients using the product.

For compliance and strict implementation.

  
**ENRIQUE A. TAYA, MD, PHSAE, FPSMID, CESO III**  
OIC – Assistant Secretary of Health  
Office for Policy and Health Systems

PNFX - 2018 - 001